This is a working overview of Neurotrophic signalling, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-06-16. Anything still debated is marked as such rather than presented as settled.
The proposed mechanism centres on neurotrophic signalling rather than direct receptor activation. Semax is reported to increase expression of brain-derived neurotrophic factor and nerve growth factor in several brain regions, and to shift the balance between excitatory and inhibitory neurotransmitter systems. Interaction with melanocortin receptors has been suggested because of the parent ACTH fragment. Many of these findings come from rodent studies, and the extent to which they translate to human physiology remains an open question.
Scientific literature on semax is unevenly distributed. A substantial share of published work originates from a small number of laboratories in Russia, while independent replication elsewhere is limited. Human data consist mostly of small trials with short follow-up, and several reported outcomes rely on subjective rating scales. Questions about how much intact peptide reaches the central nervous system after nasal administration, and how long it persists there, are still unresolved. The compound is best described as an active research subject rather than a settled pharmacological agent.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It was derived from the ACTH(4-10) fragment, a short segment of adrenocorticotropic hormone that lacks the hormonal activity associated with the full-length peptide. Researchers at the Institute of Molecular Genetics in Moscow developed the compound during the 1980s. It has been registered as a pharmaceutical product in Russia and several neighbouring countries, where it is supplied as a nasal solution, and it is also sold internationally as a research chemical.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its chain combines the first seven residues of corticotropin with a C-terminal proline-glycine-proline extension, a modification intended to slow enzymatic breakdown. The free peptide has a molecular mass near 813.9 daltons. It belongs to the class of ACTH-derived fragments studied for central nervous system activity rather than for adrenal steroid stimulation. This structural relationship to a natural hormone fragment is the usual starting point for describing the compound in the literature.
Development took place during the 1980s at institutes of the Russian Academy of Sciences, where peptide fragments of ACTH were screened for cognitive and neuroprotective effects. The compound received regulatory approval in Russia as a nasal preparation, marketed for conditions such as ischemic stroke, transient ischemic attacks, and optic nerve disorders. Registration in other countries has not followed. Most published clinical reports originate from a small number of Russian research groups, and independent replication outside that setting remains limited. The regulatory status therefore differs sharply between Russia and the rest of the world.
Laboratory work points toward modulation of neurotrophic signaling, particularly expression of brain-derived neurotrophic factor and nerve growth factor in hippocampal tissue. Studies also describe effects on monoamine turnover, inflammatory mediators, and oxidative markers. These observations come mainly from animal models and cultured cells, so the causal chain in humans is not firmly established. Whether the reported molecular changes translate into measurable clinical benefit is an open question. Reviews generally present the mechanism as plausible rather than demonstrated.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C37H51N9O10S | Calculated for the free peptide |
| Molar mass | 813.9 g/mol | Anhydrous free base |
| Peptide class | Synthetic heptapeptide | ACTH(4-10) analogue |
| Parent fragment | ACTH(4-10) | Adrenocorticotropic hormone segment |
| Developmental origin | Institute of Molecular Genetics, Moscow | Work began in the 1980s |
Pharmacological accounts link semax to melanocortin signalling and to modulation of neurotrophic factor expression, particularly brain-derived neurotrophic factor and nerve growth factor. Much of this evidence comes from rodent studies using intranasal delivery, a route chosen because it allows peptides to reach the central nervous system with limited systemic exposure. Whether the same mechanisms operate in humans at comparable magnitude remains an open question. The precise receptor or receptors responsible for the reported behavioural and neuroprotective effects have not been conclusively identified.
Clinical reports describe use in ischaemic stroke, transient ischaemic attack, optic nerve conditions, and cognitive complaints, but most of these studies are small and were conducted in a single region. Systematic reviews have generally described the evidence base as limited in size and variable in methodological quality. Randomised controlled data suitable for international regulatory assessment are scarce. As a result, major treatment guidelines outside Russia do not include the peptide, and interest in it remains largely research-driven rather than routine clinical.
Reported pharmacological work centers on neurotrophic signaling, including changes in BDNF and NGF expression in hippocampal tissue in animal models. Human data come largely from studies conducted in Russia, and how well those results generalize to other populations remains an open question. Regulatory status differs sharply by jurisdiction: Semax is a registered prescription medicine in Russia, while it holds no approved marketing status in the United States or the European Union. Outside such jurisdictions it is generally handled as a research chemical, which affects both documentation and quality expectations.
Semax is a synthetic heptapeptide whose sequence is Met-Glu-His-Phe-Pro-Gly-Pro. It was developed as a fragment analog of adrenocorticotropic hormone, modeled specifically on the ACTH(4-10) region. The first four residues reproduce that fragment, while a Pro-Gly-Pro tripeptide is appended at the C-terminus. Work on the compound originated in Russia, where it entered clinical use as an intranasal preparation. Its sequence places it among short regulatory peptides studied for effects on the central nervous system rather than on the adrenal axis.
Published research on this peptide originates mainly from Russian laboratories, and the wider international literature is comparatively thin. Studies have used rodent models of stroke, hypoxia, and memory tasks, with a smaller number of human trials reported. Reported outcomes include changes in attention and memory measures, along with effects on neurotrophic factor expression in some experiments. Small sample sizes, inconsistent dosing protocols, and limited independent replication are widely noted limitations, so the strength of the clinical evidence remains an open question.
Semax is a synthetic heptapeptide whose sequence is Met-Glu-His-Phe-Pro-Gly-Pro. The first four residues correspond to the ACTH(4-10) fragment, while the terminal Pro-Gly-Pro extension was added to improve metabolic stability. Its molecular formula is C37H51N9O10S and its monoisotopic mass is approximately 813.9 Da. The compound is classified as a peptide research chemical and as a registered pharmaceutical product in Russia, but it does not hold marketing approval in the European Union or the United States. Naming conventions vary across supplier catalogs.
== See also == Legal status of ayahuasca by country List of substances used in rituals Andrew Gallimore Changa Dimethyltryptamine/harmine Dimethyltryptamine/β-carbolines German Amazon-Jary-Expedition (1935–1937) Ibogaine Icaro Kambo (drug) Yachay
When Stephen was captured in 1141 he was imprisoned in the castle, but when Robert was captured by Stephen's forces, Matilda was forced to exchange Stephen for Robert. Her son Henry, later to become Henry II of England, was kept safe in the castle, guarded and educated by his uncle Robert. The castle was later taken into royal hands, and Henry III spent lavishly on it, adding a barbican before the main west gate, a gate tower, and magnificent hall. The castle was also used to imprison Eleanor, Fair Maid of Brittany from 1224, under relatively comfortable conditions, almost to her death in 1241. The Earl of Gloucester had founded the Benedictine priory of St James in 1137. In 1140 St Augustine's Abbey was founded by Robert Fitzharding, a wealthy Bristolian who had loyally supported the Earl and Matilda in the war. As a reward for this support he would later be made Lord of Berkeley. The abbey was a monastery of Augustinian canons. In 1148 the abbey church was dedicated by the bishops of Exeter, Llandaff, and St. Asaph, and during Fitzharding's lifetime the abbey also built the chapter house and gatehouse. In 1172, following the subjugation of the Pale in Ireland, Henry II gave Bristolians the right to reside in and trade from Dublin. The medieval Jewish community of Bristol was one of the smaller communities in England. The Jews of Bristol were accused in a blood libel in 1183, but not many details are known. At the end of the 12th century, an archa was established in the city, without which Jews would not have been legally allowed to conduct business.
=== Neurotoxic reactions === Headache, mild depression, mental confusion, and delirium have been described in patients receiving chloramphenicol. Optic and peripheral neuritis have been reported, usually following long-term therapy. If this occurs, the drug should be promptly withdrawn. It is theorized that this is caused by chloramphenicol's effects on the metabolism of B-Vitamins, specifically B-12.
=== Effects on inflammation === PGLYRP2 directly and indirectly affects inflammation and plays a role in maintaining anti- and pro-inflammatory homeostasis in the intestine, skin, joints, and brain. Hydrolysis of peptidoglycan by PGLYRP2 diminishes peptidoglycan's pro-inflammatory activity. This effect is likely due to amidase activity of PGLYRP2, which separates the stem peptide from MurNAc in peptidoglycan and destroys the motif required for the peptidoglycan-induced activation of NOD2 (nucleotide-binding oligomerization domain-containing protein 2), one of the proinflammatory peptidoglycan receptors. PGLYRP2-deficient mice are more susceptible than wild type mice to dextran sodium sulfate (DSS)-induced colitis, which indicates that PGLYRP2 protects mice from DSS-induced colitis. Intestinal microbiome is important for this protection, because this increased sensitivity to colitis could be transferred to wild type germ-free mice by microbiome transplant from PGLYRP2-deficient mice. PGLYRP2-deficient mice are more susceptible than wild type mice to the development of experimentally induced psoriasis-like inflammation, which indicates that PGLYRP2 is anti-inflammatory and protects mice from this type of skin inflammation. This pro-inflammatory effect in PGLYRP2-deficient mice is due to the increased numbers and activity of T helper 17 (Th17) cells and decreased numbers of T regulatory (Treg) cells. PGLYRP2-deficient mice are more susceptible than wild type mice to S.
elution The process of extracting one material from another by washing with a solvent. Elution works by running a solution containing an analyte past an adsorbent matrix designed to selectively bind the analyte molecules, and subsequently washing the adsorbent/analyte complex with a solvent, known as an eluent. The solvent molecules displace the analyte by binding to the adsorbent in its place, allowing the analyte, now part of the eluate, to be carried out of the complex and into a collector for analysis.
Sources: en.wikipedia.org
Navy Warrant Officer Class 1 D Lennon Chief Petty Officer M Rodway Army Warrant Officer Class 1 Matthew James Anderson, Royal Corps of Signals Warrant Officer Class 1 Rupert St John Hardington Banfield, , Army Air Corps Warrant Officer Class 1 Peter Bernthal, Corps of Royal Electrical and Mechanical Engineers Staff Sergeant Troy David Binding Corps of Royal Electrical and Mechanical Engineers Warrant Officer Class 2 Aarron David Butterworth, Corps of Royal Engineers Warrant Officer Class 1 (now Captain) Adam Daniel Cooksey, Royal Regiment of Artillery Warrant Officer Class 1 (now Captain) Leslie Trevor Dinsmore, Corps of Royal Electrical and Mechanical Engineers Warrant Officer Class 2 Darren Lee Duckitt, The Royal Yorkshire Regiment Warrant Officer Class 2 Kulbahadur Ghale, The Royal Gurkha Rifles Warrant Officer Class 1 (now Captain) Marc Kevin Giles, , The Mercian Regiment Warrant Officer Class 1 Philip John Greenway, Royal Regiment of Artillery Warrant Officer Class 1 Adam Charles Ireland, The Parachute Regiment Warrant Officer Class 1 Manojkumar Jugjali, The Royal Gurkha Rifles Warrant Officer Class 1 Carley Lorraine Lambert, Royal Regiment of Artillery Warrant Officer Class 1 James Lee Lightfoot, Royal Regiment of Artillery Warrant Officer Class 1 (now Captain) Daniel Andrew Long, The Rifles Warrant Officer Class 1 James Derek Mayoh, Royal Regiment of Artillery Warrant Officer Class 1 (now Captain) Stuart Russell McCreadie, Royal Corps of Signals Warrant Officer Class 1 Peter Steven Meager, Corps of Royal Electrical and Mechanical Engineers Warrant Officer Class 1 (now Captain) Ryan Daniel O'Neill, The Royal Regiment of Scotland Warrant Officer Class 1 James Edward Phillips, Corps of Royal Electrical and Mechanical Engineers Warrant Officer Class 2 Michael John Potts, Royal Army Medical Corps Warrant Officer Class 2 Prakash Rai, Royal Army Medical Corps Warrant Officer Class 2 Kyle Reains, Irish Guards Warrant Officer Class 1 James Wright Reid, Corps of Royal Electrical and Mechanical Engineers Warrant Officer Class 1 James Oliver Richardson, Royal Regiment of Artillery Warrant Officer Class 1 Aran Christopher Rushe, Royal Army Medical Corps Warrant Officer Class 1 Grant Spencer Sewell-Jones, Royal Corps of Army Music Warrant Officer Class 1 Paul Sheenan, Corps of Royal Electrical and Mechanical Engineers Warrant Officer Class 1 Melanie Louise Silvester, Adjutant General's Corps (Staff and Personnel Support Branch) Warrant Officer Class 1 (now Captain) Garry Andrew Smurthwaite, The Parachute Regiment Warrant Officer Class 2 David Robert John Steel, The Royal Scots Dragoon Guards Warrant Officer Class 1 John Ian Sweeney, Army Air Corps Warrant Officer Class 2 (now Captain) Trevor Albert Tuhey, Royal Army Physical Training Corps Warrant Officer Class 1 Russell James Underwood, Corps of Royal Electrical and Mechanical Engineers Warrant Officer Class 2 George Ferguson Francis Wong Vesi, Adjutant General's Corps (Staff and Personnel Support Branch) Warrant Officer Class 1 (now Captain) Jonathan George Werrett, The Mercian Regiment Warrant Officer Class 1 Joseph Thomas Williams, Corps of Royal Electrical and Mechanical Engineers Warrant Officer Class 1 Michael James Williams, Royal Corps of Signals Warrant Officer Class 1 David Wood, Corps of Royal Electrical and Mechanical Engineers Warrant Officer Class 1 Craig Michael Woodall, Royal Army Veterinary Corps Warrant Officer Class 2 Robert Steven Young, Welsh Guards Air Force Warrant Officer (now Flight Lieutenant) J. Blinkhorn Warrant Officer (now Flight Lieutenant) H. Dimeck Warrant Officer (now Flight Lieutenant) F.E. Hunt Warrant Officer D.P. Burke Warrant Officer W.O.R Clements Warrant Officer N.W. Cook Master Aircrew A.R. Davey, Warrant Officer J.C. Foxall Warrant Officer D.G. Jackson Warrant Officer K.E. Jones Warrant Officer E.L. Kerslake Warrant Officer M.E. Larkin Warrant Officer D.A. Lawrence Warrant Officer R. Laycock Warrant Officer B. Moore Warrant Officer C.L.S Old Master Aircrew S.R. Parsons Warrant Officer K.N. Phillips Warrant Officer S.G. Rowbotham Warrant Officer A. Wilson Warrant Officer P.B. Wilson, Warrant Officer S.M. Wooles Acting Warrant Officer K.S. Edwards Acting Warrant Officer A.S. MacDonald Flight Sergeant M.J. Moore Flight Sergeant J.C. O'Grady Flight Sergeant J.A. Simpkins Flight Sergeant C.A. Smith Flight Sergeant P.S. Ware Flight Sergeant L.A. Williams Chief Technician D.G. Bristow Sergeant E.P. Jones
=== 1971-2000 === In 1971, Revlon acquired DCL BioMedical, a clinical laboratory business founded in 1968. In 1974, it changed its name to National Health Laboratories Incorporated. By 1977, it operated clinical testing laboratories in 13 cities and maintained auxiliary service centers and satellite laboratories in 15 other cities. In 1978, it acquired American Biomedical Corporation, giving it operations in the Southwestern United States and data processing technology. In 1985, Revlon was acquired by Ronald Perelman. Revlon divested its other businesses and a major stake in the company was acquired by MacAndrews & Forbes. In 1988, National Health Laboratories became a public company via an initial public offering on the NASDAQ exchange. In 1989, the company generated revenue of about US$400 million, with about US$70 million in earnings. In the early 1990s, worries about malpractice lawsuits led doctors to conduct more clinical testing before diagnosing, which increased business for the company. In 1990, the company's revenues reached US$500 million, with over US$70 million in earnings. In 1991, National Health Laboratories moved its listing from the NASDAQ to the New York Stock Exchange. In June 1992, the company offered to acquire Damon Corporation for $260 million in cash and stock. However, the company was outbid by Corning Inc., which acquired Damon for $370 million. By 1993, the company had 22 major laboratories. On March 8, 1994, National Health Laboratories Inc. reorganized as a holding company, National Health Laboratories Holdings Inc.
=== Domains === F: Formylation (optional) A: Adenylation (required in a module) PCP: Thiolation and peptide carrier protein with attached 4'-phospho-pantetheine (required in a module) C: Condensation forming the amide bond (required in a module) Cy: Cyclization into thiazoline or oxazolines (optional) Ox: Oxidation of thiazolines or oxazolines to thiazoles or oxazoles (optional) Red: Reduction of thiazolines or oxazolines to thiazolidines or oxazolidines (optional) E: Epimerization into D-amino acids (optional) NMT: N-methylation (optional) TE: Termination by a thio-esterase (only found once in a NRPS) R: Reduction to terminal aldehyde or alcohol (optional) X: Recruits cytochrome P450 enzymes (optional)
In 2001, a more complete juvenile tyrannosaur (nicknamed "Jane", accession number BMRP 2002.4.1), suggested to belong to the same species as the original Nanotyrannus specimen, was uncovered. This discovery prompted a conference on tyrannosaurs focused on the issues of the validity of Nanotyrannus, held at the Burpee Museum of Natural History in 2005. Several paleontologists who had previously published opinions that N. lancensis was a valid species, including Currie and Williams, saw the discovery of "Jane" as a confirmation that Nanotyrannus was, in fact, a juvenile T. rex. Peter Larson continued to support the hypothesis that Nanotyrannus lancensis was a separate but closely related species, and also argued that Stygivenator (LACM 28471), which is generally considered to be a juvenile of Tyrannosaurus rex, could be a younger specimen of Nanotyrannus. In 2011, news reports about a 2006 discovery of a new, virtually complete theropod specimen found alongside a ceratopsid were made. The specimens were studied by Robert Bakker and Peter Larson on-site, who identified the ceratopsian as Triceratops and the theropod as Nanotyrannus. It was impossible to determine whether the theropod specimen, nicknamed "Bloody Mary", was distinct from T. rex, as the specimen remained in private hands until 2020, when the ownership of the specimen was decided by the Montana Supreme Court to be given to the landowners Mary Anne and Lige Murray. The fossil was acquired by the North Carolina Museum of Natural Sciences in 2020.
Sources: en.wikipedia.org
Semax is based on the ACTH(4-10) fragment, a seven-amino-acid segment of adrenocorticotropic hormone. The synthetic peptide retains the core sequence while removing regions associated with endocrine activity. This modification is intended to isolate effects on the nervous system.
It is registered for clinical use in Russia and a few other countries, typically as a nasal drop formulation. It does not hold approval from the United States Food and Drug Administration or the European Medicines Agency. Outside those markets it is generally handled as a research chemical.
The compound was developed in Moscow and the earliest studies were conducted there, so the primary literature is largely in Russian-language journals. Translation and indexing have been incomplete, which limits access for outside researchers. Independent groups have since published some work, but the total volume remains modest.
Semax is a synthetic seven-amino-acid peptide derived from a fragment of corticotropin. It is used in Russia as a nasal preparation, while elsewhere it is studied as a research compound. It is not approved as a medicine in most countries.